Pricing & Reimbursement: Unlocking The Potential For ATMPs
Source: Precision ADVANCE
Pressure is being applied to the ‘traditional’ healthcare reimbursement model. As novel therapies continue to propel towards commercialization, healthcare systems and manufacturers are being asked to embrace evidence-based pricing strategies to lessen the burden of upfront costs. Our panelists will discuss how stakeholders across the drug development continuum can work together to manage availability and affordability, while reducing patient-adverse outcomes for these life-saving treatments.
In this panel you will learn about:
- The current state of therapy pricing, reimbursement, and value demonstration
- Solutions for improving patient access
- How to better understand durability of effect and long-term data requests
- Shifting from rare to prevalent indications
- Understanding payer and HTA engagement in the US and EU markets
VIEW THE WEBINAR!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Precision ADVANCE
This website uses cookies to ensure you get the best experience on our website. Learn more